500674 Share Price Performance
₹0
-5177.40 (-100.00%)
Price ₹0
Fair Value₹4,579.00
Share Pricen/a
Narrative Update • Aug 09
Sanofi India Limited Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 5 Fair Values set on narratives written by author
500674 Community Narratives
AN
Fair Value
·Fair Value ₹4.58k 28.5% undervalued intrinsic discount
Diabetes Care Focus And Premium Insulin Mix Will Drive Long-Term Earnings Power
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value ₹5.55k 41.0% undervalued intrinsic discount
AI And Diabetes Focus Will Reshape Margins And Exports Over Time
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value ₹3.52k 7.0% undervalued intrinsic discount
Diabetes Focus And AI Execution Will Face Headwinds Yet Ultimately Support A Healthier Outlook
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AI And Diabetes Focus Will Reshape Margins And Exports Over Time
Sanofi India is leaning harder into diabetes care while using AI to fine-tune how it sells, stocks, and produces medicines—moves that could steadily lift profits if they work. The flip side is heavy reliance on a narrow set of diabetes products and on exports and partners to drive growth, which could disappoint if demand shifts or execution slips.Read more
AN
₹5.55k
41.0% undervalued intrinsic discount
Fair Value
Revenue
9.49% p.a.
Profit Margin
22.42%
Future PE
34.16x
Price in 2029
₹7.88k
Diabetes Focus And AI Execution Will Face Headwinds Yet Ultimately Support A Healthier Outlook
Sanofi India is betting more heavily on diabetes medicines and new digital tools, but the shift could be bumpier than the growing need for treatment might suggest. See what could slow down growth—from export setbacks to tougher competition for newer diabetes products—and what would need to go right for the story to improve.Read more
AN
₹3.52k
7.0% undervalued intrinsic discount
Fair Value
Revenue
9.53% p.a.
Profit Margin
22.48%
Future PE
22.01x
Price in 2029
₹5.01k
Diabetes Care Focus And Premium Insulin Mix Will Drive Long-Term Earnings Power
Sanofi India is leaning hard into diabetes care, betting that newer insulin options and stronger doctor outreach can keep demand growing as more patients start treatment earlier. The upside comes from selling more premium therapies and improving how it operates, but slower export recovery and fast-moving new diabetes drugs could curb long-term growth.Read more
AN
₹4.58k
28.5% undervalued intrinsic discount
Fair Value
Revenue
9.83% p.a.
Profit Margin
23.75%
Future PE
26.88x
Price in 2029
₹6.51k
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
500674: Future Leadership Transition Will Support Confidence In Long Term Earnings
Fair Value: ₹5.55k 41.0% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
500674: Board Transition And Revised Assumptions Will Shape A Measured Outlook
Fair Value: ₹3.52k 7.0% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
500674: Board Leadership Transition Will Drive Future Confidence In Earnings
Fair Value: ₹4.58k 28.5% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Sanofi India Limited Key Details
About 500674
- Founded
- 1956
- Employees
- 1097
- CEO
- WebsiteView website
Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company offers pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, anti-infectives, and central nervous system under the Lantus, Toujeo, Soliqua, Clexane, Amaryl, Cardace, Lasix, Lasilactone, Glimepiride, Cetapin, Targocid, Frisium, Targocio, Combiflam, DePura, Allegra, Baralgan, BUSCOGAST, Dulcoflex, Enterogermina, Novalgin, and Avil brands through independent distributors. It also exports its products. The company was formerly known as Aventis Pharma Limited and changed its name to Sanofi India Limited in May 2012. The company was incorporated in 1956 and is headquartered in Mumbai, India. Sanofi India Limited operates as a subsidiary of Hoechst GmbH.
